Cetuximab (EGFR inhibitor)(Eli Lilly / Merck KGaA)은 EGFR 표적 항체로, Advanced Solid Tumor; NSCLC 영역에서 개발·상용화 중입니다. 작용기전: inhibits the PI3K/AKT/GSK3β signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 50.5% (ClinicalTrials.gov NCT04511533). PK: t½ 112 days. 차별점: novel theoretical foundation for the targeted therapy of HBV-HCC using quercetin.
EGFR
Advanced Solid Tumor; NSCLC
Active
Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical
-linkers
linkers are disclosed in this revision
Lentiviral transfection was used to construct HCC cell lines overexpressing HBx and EGFR,
novel theoretical foundation for the targeted therapy of HBV-HCC using quercetin
inhibits the PI3K/AKT/GSK3β signaling
cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and on-target off-tumor effects r
payload-linkers are disclosed in this revision
PD-L1)-positive
Resistance to EGFR-targeted therapies, including cetuximab, remains a major barrier to effective treatment of head and neck squamous
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Cetuximab (EGFR inhibitor)(Eli Lilly / Merck KGaA)은 EGFR 표적 항체로, Advanced Solid Tumor; NSCLC 영역에서 개발·상용화 중입니다. 작용기전: inhibits the PI3K/AKT/GSK3β signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 50.5% (ClinicalTrials.gov NCT04511533). PK: t½ 112 days. 차별점: novel theoretical foundation for the targeted therapy of HBV-HCC using quercetin.
EGFR
Advanced Solid Tumor; NSCLC
Active
Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical
-linkers
linkers are disclosed in this revision
Lentiviral transfection was used to construct HCC cell lines overexpressing HBx and EGFR,
novel theoretical foundation for the targeted therapy of HBV-HCC using quercetin
inhibits the PI3K/AKT/GSK3β signaling
cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and on-target off-tumor effects r
payload-linkers are disclosed in this revision
PD-L1)-positive
Resistance to EGFR-targeted therapies, including cetuximab, remains a major barrier to effective treatment of head and neck squamous
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.